{
    "clinical_study": {
        "@rank": "151482", 
        "arm_group": {
            "arm_group_label": "Oxcarbazepine and Morphine", 
            "arm_group_type": "Other", 
            "description": "Patients must be on stable or increasing doses of greater than or equal to 180 mg of morphine sulfate per day. Morphine is taken orally for 42 days.\nIn addition to Morphine, patients will also receive oral Oxcarbazepine 150 mg, every 12 hours, for 2 weeks, then increase the dose to 300 mg, every 12 hours, for 2 weeks and then increase the dose to 450 mg, every 12 hours, for the final 2 weeks.  Patients will take oral tablets of oxcarbazepine for a total of 42 days."
        }, 
        "brief_summary": {
            "textblock": "This is an open-label, single arm, Phase Ib dose escalation study of Oxcarbazepine with\n      morphine in patients with refractory cancer pain. The primary endpoint is to evaluate the\n      safety and toxicity of the combination of Oxcarbazepine plus morphine. The secondary\n      endpoints are improving pain control, reduce morphine use and improve the quality of life."
        }, 
        "brief_title": "Oxcarbazepine Plus Morphine in Patients With Refractory Cancer Pain", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Cancer", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Written informed consent and HIPAA authorization for release of\n             personal health information.\n\n             \u2022\u2265 18 years old at the time of informed consent\n\n          -  Patients with histologically confirmed diagnosis of cancer NOTE: Patients with active\n             cancer or post treatment are allowed on the study.\n\n          -  Patients must be receiving stable or increasing doses of morphine for 1-2 weeks prior\n             to registration for protocol therapy.\n\n        NOTE: Switching patient from current pain regimen to morphine equivalent for at least 1-2\n        weeks prior to registration for protocol therapy is required.\n\n          -  Requiring greater than or equal to 180 mg of morphine per day. See Appendix 1 for\n             Morphine Conversion Calculator.\n\n          -  Inadequately controlled pain even with the use of morphine (VAS score >5) See\n             Appendix 8\n\n          -  Rescue pain medications are allowed this may include the use of NSAIDS or Tylenol as\n             well as morphine IR.\n\n          -  ECOG Performance Status of 0-2\n\n          -  Ability to swallow and tolerate oral tablets.\n\n          -  Patients getting radiation therapy are allowed at the discretion of the treating\n             physician.\n\n          -  Females of childbearing potential must have a negative pregnancy test NOTE:  Females\n             are considered of child bearing potential unless they are surgically sterile (they\n             have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy)\n             or they are postmenopausal (> 12 months since last menses).\n\n        NOTE: Females using hormonal contraceptives should be switched to non-hormonal forms of\n        contraception.\n\n        The following laboratory values must be obtained. Patient with aplastic anemia will be\n        excluded.\n\n          -  White blood cell count (WBC) \u2265 3.0 K/mm3\n\n          -  Absolute neutrophil count \u2265 1.5 K/mm3\n\n          -  Hemoglobin (Hgb) \u2265 9 g/dL\n\n          -  Platelets \u2265 75 K/mm3\n\n          -  Creatinine \u2264 1.5 mg/dl\n\n          -  Bilirubin \u2264 1.5 x ULN\n\n          -  Aspartate aminotransferase (AST, SGOT) \u2264 3 x ULN\n\n          -  Alanine aminotransferase (ALT, SGPT)  \u2264 3 x ULN\n\n        Exclusion Criteria:\n\n        \u2022 Active central nervous system (CNS) metastases.  Patients with neurological symptoms\n        should undergo a head CT scan or brain MRI to exclude brain metastasis, at the discretion\n        of the treating physician.\n\n        NOTE:  Patients with prior brain metastasis may be considered if they have completed their\n        treatment for brain metastasis, no longer require corticosteroids, and are asymptomatic.\n\n        \u2022 Concurrent use of adjuvant medication such as but not limited to: gabapentin, pregabalin\n        or duloxetine etc.\n\n        NOTE:  Patients on gabapentin or pregabalin can be considered if they can be tapered off\n        before enrolling on the study.\n\n          -  Treatment with any investigational agent within 30 days prior to registration for\n             protocol therapy.\n\n          -  Patient with rapidly escalating pain that require hospitalization or an intravenous\n             opioid therapy\n\n          -  Concurrent participation in a clinical trial which involves another investigational\n             agent.\n\n          -  Concurrent use of medications that are strong CYP3A4 inhibitors within 14 days prior\n             to registration for protocol therapy as Oxcarbazepine is strong CYP3A4 inducer. See\n             Appendix 7.\n\n        NOTE: Concurrent use of other CYP3A4 inhibitors may be allowed at the discretion of the\n        treating physician or principal investigator.\n\n          -  Allergic reaction to carbamazepine or oxcarbazepine (HLA-B1502)\n\n          -  Allergy or other contraindication to morphine sulphate\n\n          -  Opiate-induced uncontrolled constipation or bowel obstruction\n\n          -  Patient who lives alone.\n\n          -  Female who is pregnant or breastfeeding\n\n          -  Patient who has a diagnosis of epilepsy and/or is currently taking anti-epileptic\n             drugs"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "12", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 24, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02078089", 
            "org_study_id": "IUCRO-0453"
        }, 
        "intervention": [
            {
                "arm_group_label": "Oxcarbazepine and Morphine", 
                "description": "Morphine will be given to patients as part of their standard care", 
                "intervention_name": "Morphine", 
                "intervention_type": "Drug", 
                "other_name": "Morphine Sulfate"
            }, 
            {
                "arm_group_label": "Oxcarbazepine and Morphine", 
                "description": "Can be taken with or without food at the same time as morphine. Morphine will be provided to patients free of charge.", 
                "intervention_name": "Oxcarbazepine", 
                "intervention_type": "Drug", 
                "other_name": "Tileptal"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Morphine", 
                "Carbamazepine", 
                "Oxcarbazepine"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Refractory cancer pain", 
        "lastchanged_date": "March 3, 2014", 
        "location": [
            {
                "contact": {
                    "email": "anefoste@iupui.edu", 
                    "last_name": "Anne Younger, R.N", 
                    "phone": "317-274-0951"
                }, 
                "contact_backup": {
                    "email": "calbany@iu.edu", 
                    "last_name": "Costantine Albany, M.D.", 
                    "phone": "317-278-4519"
                }, 
                "facility": {
                    "address": {
                        "city": "Indianapolis", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "46202"
                    }, 
                    "name": "Indiana Univeristy Health Hospital"
                }, 
                "investigator": {
                    "last_name": "Costantine Albany, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "anefoste@iupui.edu", 
                    "last_name": "Anne Younger, R.N", 
                    "phone": "317-274-0951"
                }, 
                "contact_backup": {
                    "email": "calbany@iu.edu", 
                    "last_name": "Costantine Albany, M.D.", 
                    "phone": "317-278-4519"
                }, 
                "facility": {
                    "address": {
                        "city": "Indianapolis", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "46202"
                    }, 
                    "name": "Indiana University Simon Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Costantine Albany, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase Ib Study of Oxcarbazepine Plus Morphine in Patients With Refractory Cancer Pain", 
        "overall_contact": {
            "email": "anefoste@iupui.edu", 
            "last_name": "Anne Younger, R.N", 
            "phone": "317-274-0951"
        }, 
        "overall_contact_backup": {
            "email": "calbany@iu.edu", 
            "last_name": "Costantine Albany, M.D.", 
            "phone": "317-278-4519"
        }, 
        "overall_official": {
            "affiliation": "Indiana University", 
            "last_name": "Costantine Albany, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Evaluate the safety and toxicity of oxcarbazepine in combination with morphine", 
            "measure": "Number of patients with adverse events as a measure of safety and toxicity", 
            "safety_issue": "Yes", 
            "time_frame": "1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02078089"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Evaluate changes in pain control after adding oxcarbazepine to morphine", 
                "measure": "Changes in Pain control", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "description": "Evaluate changes morphine consumption after adding oxcarbazepine to morphine", 
                "measure": "Changes in Consumption", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "description": "Evaluate changes in Quality of Life after adding oxcarbazepine to morphine", 
                "measure": "Changes in Quality of Life", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }
        ], 
        "source": "Indiana University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Indiana University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}